Hepatorenal syndrome

Contributions to Nephrology

Volumn 174, Issue , 2011, Pages 46-55

  Angeli, Paolo ^a   Morando, Filippo ^a   Cavallin, Marta ^a   Piano, Salvatore ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; DRUG DERIVATIVE; LYPRESSIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT;

ARTICLE; HEPATORENAL SYNDROME; HUMAN; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY;

ALBUMINS; HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; LYPRESSIN; VASOCONSTRICTOR AGENTS;

EID: 84925861380     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000329235     Document Type: Article

References (47)

1. Gines A, Escorsell A, Gines P, et al: Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236. (Pubitemid 23234041)
2. Schrier RW, Arroyo V, Bernardi M, et al: Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157.
3. Arroyo V, Gines P, Gerbes AL, et al: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176. (Pubitemid 26012105)
4. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V: Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the International Ascites Club. Gut 2007;56:1310-1318. (Pubitemid 47300435)
5. Gines P, Guevara M, Arroyo V, Rodes J: Hepatorenal sindrome. Lancet 2003;362:1819-1827.
6. Follo A, Llovet JM, Navasa M, et al: Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501. (Pubitemid 24359062)
7. Fernandez J, Navasa M, Planas R, et al: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-824. (Pubitemid 47374144)
8. Fasolato S, Angeli P, Dallagnese L, et al: Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007;45:223-229. (Pubitemid 46144382)
9. Terra C, Guevara M, Torre A, et al: Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005;129:1944-1953. (Pubitemid 41772972)
10. Ruiz del Arbor L, Urman J, Fernandez J, et al: Systemic, renal and hepatic haemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218. (Pubitemid 37314829)
11. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al: Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-447. (Pubitemid 41061097)
12. Alqahtani SA, Fouad TR, Lee SS: Cirrhotic cardiomyopathy. Sem Liver Dis 2008;28:59-69. (Pubitemid 351326533)
13. Gonwa TA, Klintmalm GB, Levy M, et al: Impact of pretransplant renal function on survival after liver transplantation. Transplantion 1995;59:361-365.
14. Navasa M, Feu F, Garcia-Pagan JC, Jimenez W, et al: Hemodynamic and humoral changes after liver-transplantation in patients with cirrhosis. Hepatology 1993;17:355-360. (Pubitemid 23072807)
15. Schlitt HJ, Barkmann A, Boker KH, et al: Replacement of calcineurin inhibitors with mycophenolate mofetil in livertransplant patients with renal dysfunction: a randomised controlled study. Lancet 2001;357:587-591. (Pubitemid 32179611)
16. Restuccia T, Ortega R, Guevara M, et al: Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case control study. Liver Transpl 2004;40:140-146. (Pubitemid 38064723)
17. Narahara Y, Kanazawa H, Taki Y, et al: Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009;24:1791-1797.
18. Guevara M, Gines P, Fernandez-Esparrach G, et al: Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35241.
19. Gulberg V, Bilzer M, Gerbes AL: Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and albumin. Hepatology 1999;30:870-875. (Pubitemid 29458273)
20. Ganne-Carrie N, Hadegue A, Mathurin P, et al: Hepatorenal syndrome: long-term treatment with terlipressin as bridge to liver transplantation. Dig Dis Sci 1996;41:1054-1056. (Pubitemid 26227874)
21. Le Moine O, El Nawar A, Jagodzinski R, et al: Treatment with terlipressin as a bridge to translantation in a patient with hepatorenal syndrome. Acta Gastroenterol Belg 1998;61;268-270. (Pubitemid 28280643)
22. Duhamel C, Mauillon J, Berkelmans J, Bourienne A, Tranvuez JL: Hepatorenal syndrome in cirrhotic patients: terlipressin is a safe and efficient treatment; propoanolol and digitalic treatment: precipitating and preventing factors? Am J Gastroenterol 2000;95:2984-2985.
23. Halimi C, Bonnard P, Bernard B, et al: Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-158. (Pubitemid 34163994)
24. Mulkay JP, Louis H, Donckier V, et al: Longterm terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroelerologica Belg 2001;64:15-19. (Pubitemid 32291099)
25. Uriz J, Gines P, Cardenas A, et al: Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-48. (Pubitemid 30418933)
26. Ortega R, Gin? P, Uriz J, et al: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941-948.
27. Solanki P, Chawala A, Garg R, et al: Beneficial effects of terlipressin in hepatorenal sindrome: a prospective, randomized placebo- controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-156. (Pubitemid 36349860)
28. Moreau R, Durand F, Poynard T, et al: Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930. (Pubitemid 34267275)
29. Colle I, Durand F, Pessione F, et al: Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002;17:882-888.
30. Angeli P, Guarda S, Fasolato S, et al: Switch therapy with ciprofloxacin versus intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006;23:75-84. (Pubitemid 43381169)
31. Gerbes AL, Huber E, Gberg V: Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009;137:1179.
32. Angeli P, Volpin R, Gerunda G, et al: Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology 1999;29:1690-1697. (Pubitemid 29247040)
33. Wong F, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64. (Pubitemid 38868923)
34. Esrailian E, Pantageo ER, Kyulo NL, Hu KQ, Runyon BA: Octretide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-748.
35. Skagen C, Einstein M, Lucey MR, Said A: Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009;43:680-685.
36. Devoux C, Zanditenas D, Hezode C, et al: Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-380. (Pubitemid 34810356)
37. Sharma P, Kumar A, Sharma BC, Sarin SK: An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689-1697.
38. Piano S, Morando F, Fasolato S, et al: Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to meld score in the allocation system to liver transplantation? J Hepatol 2011, E-pub ahead of print.
39. Sanyal A, Boyer T, Garcia-Tsao G, et al: A randomized, prospective, double blind placebo- controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-1368. (Pubitemid 351615358)
40. Martin-Llahi MM, Pepin MN, Guevara M, et al: Terlipressin and albumin versus albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359. (Pubitemid 351626950)
41. Gluud LL, Christensen K, Krag A: Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-584.
42. Nazar A, Pereira GH, Guevara M, et al: Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 HRS Hepatology 2010;51:219-226.
43. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al: Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2010 E-pub ahead of print.
44. Trawale JM, Paradis V, Rautou PE, et al: The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 2010;30:725-732.
45. Wang W, Mitra A, Poole B, et al: Endothelial nitric oxide synthase-deficient mice exhibit increased susceptibility to endotoxininduced acute renal failure. Am J Physiol Renal Physiol 2004;287:F1044-F1048. (Pubitemid 39391102)
46. Zhou Z, Gengaro P, Wang W, et al: Role of NF-?B and PI 3-kinase/Akt in TNF- α-induced cytotoxicity in microvascular endothelial cells. Am J Physiol Renal Physiol 2008;295:F932-F941.
47. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M: Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-1368. (Pubitemid 36054926)